Journal of Inflammation is published continuously online-only and so we encourage you to sign up to receive free email alerts to keep up to date with all of the latest research by registering here.
Editors' Pick: SARS-CoV-2 COVID-19 Susceptibility and Lung Inflammatory Storms by Smoking and Vaping
Aging, smoking/vaping results in severe disease outcome and mortality amongst COVID-19 patients. SARS-CoV-2 with a membrane spike glycoprotein furin along with its receptor ACE2 and TMPRSS2 protease are increased by smoking/vaping in lung epithelium rendering viral entry and augmented infection. This results in a ‘cytokine storm’ involving excessive production of pro-inflammatory cytokines/chemokines. This review therefore discusses the impact of smoking /vaping on the key inflammatory mechanisms following Covid-19 infection and the possible therapeutic strategies required to overcome this excessive inflammatory response.
Testing the boundaries of the brain’s immune system
Guest Editors:
Laura McCulloch: University of Edinburgh, UK
Andrew Greenhalgh: University of Manchester, UK
Submission Status: Open until 31 October 2023
Trending Articles
View which articles have been recently trending
Articles
-
-
Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance
-
Anti-inflammatory activity of non-selective PDE inhibitor aminophylline on the lung tissue and respiratory parameters in animal model of ARDS
-
Components of the sympathetic nervous system as targets to modulate inflammation – rheumatoid arthritis synovial fibroblasts as neuron-like cells?
-
Anti-inflammatory therapy of atherosclerosis: focusing on IKKβ
-
Anti-inflammatory potential of Quercetin in COVID-19 treatment
-
Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration
-
The Journal of Inflammation
-
Mesenchymal stem cells avoid allogeneic rejection
-
Antioxidant and potential anti-inflammatory activity of extracts and formulations of white tea, rose, and witch hazel on primary human dermal fibroblast cells
Sign up to receive article alerts
Aims and scope
Journal of Inflammation is an open access, peer-reviewed online journal publishing articles on all aspects of research into inflammation. Non-research articles are specially commissioned by the Editors-in-Chief.
Announcing the launch of In Review
Journal of Inflammation, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Submit your review
Journal of Inflammation welcomes review articles on a variety of different topics relating to the scope of the journal. Submit your review today.
For further queries or to discuss the limited funds which may be available to cover the article-processing charge, please contact the editorial team.
Editor profiles
Prof Paul Kirkham, Editor-in-Chief
Prof Kirkham is Professor of Cell Biology at the University of Wolverhampton and a fellow of the HEA. His research interests focus on understanding the mechanisms of disease pathogenesis driven by oxidative stress and its impact on cell function and inflammation, particularly in relation to respiratory disease.
Prof Adriano Rossi, Editor-in-Chief
Prof Rossi holds the position of Personal Chair in Respiratory and Inflammation Pharmacology at the University of Edinburgh. Prof Rossi is a Fellow of the Society of Biology and a Fellow of the British Pharmacological Society. His research involves investigating the cellular processes and signalling mechanisms controlling inflammation with a focus on understanding inflammation resolution.
Affiliated with the British Inflammation Research Association (BIRAs).
Follow
Annual Journal Metrics
-
Citation Impact
6.283 - 2-year Impact Factor (2021)
5.099 - 5-year Impact Factor (2021)
0.989 - Source Normalized Impact per Paper (SNIP)
1.212 - SCImago Journal Rank (SJR)Speed
20 days to first decision for all manuscripts (Median)
74 days to first decision for reviewed manuscripts only (Median)Usage
487,727 Downloads (2021)
434 Altmetric mentions (2021)